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Abstract
Introduction: Access to antiretroviral therapy (ART) has increased greatly in sub-Saharan Africa. However many patients do
not enrol timely into HIV care and treatment after HIV diagnosis. We studied enrolment into care and treatment and
determinants of non-enrolment in Rwanda.
Methods: Data were obtained from routine clinic registers from eight health facilities in Rwanda on patients who were
diagnosed with HIV at the antenatal care, voluntary counselling-and-testing, outpatient or tuberculosis departments
between March and May 2009. The proportion of patients enrolled into HIV care and treatment was calculated as the
number of HIV infected patients registered in ART clinics for follow-up care and treatment within 90 days of HIV diagnosis
divided by the total number of persons diagnosed with HIV in the study period.
Results: Out of 482 patients diagnosed with HIV in the study period, 339 (70%) were females, and the median age was 29
years (interquartile range [IQR] 24–37). 201 (42%) enrolled into care and treatment within 90 days of HIV diagnosis. The
median time between testing and enrolment was six days (IQR 2–14). Enrolment in care and treatment was not significantly
associated with age, sex, or department of testing, but was associated with study site. None of those enrolled were in WHO
stage 4. The median CD4 cell count among adult patients was 387 cells/mm
3 (IQR: 242–533 cells/mm
3); 81 of 170 adult
patients (48%) were eligible to start ART (CD4 count,350 cells/mm
3 or WHO stage 4). Among those eligible, 45 (56%)
started treatment within 90 days of HIV diagnosis.
Conclusion: Less than 50% of diagnosed HIV patients from eight Rwandan health facilities had enrolled into care and
treatment within 90 days of diagnosis. Improving linkage to care and treatment after HIV diagnosis is needed to harness the
full potential of ART.
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Introduction
In many sub Saharan African countries access to antiretroviral
therapy (ART) has increased greatly in recent years [1,2]. Linkage
to care and treatment after a positive HIV test is crucial to harness
the potential of ART; studies have shown that mortality among
diagnosed HIV patients awaiting ART can be unacceptably high
[3–5]. Enrolment into HIV care has been studied in several Sub
African settings and the proportion of HIV positive patients
enrolled into HIV care varied from a low 38% in a study from
urban Zambia [6] to 68% six months after HIV diagnosis in rural
northern Tanzania [7] and south-west Uganda [8].
Rwanda adopted a national ART program in 2003 and since
then access to ART has increased fast. In Rwanda ART is
available from 295 clinics, both urban and rural, throughout the
country [9]. Rwanda is a densely populated country and the
average distance to clinics is short compared to most sub Saharan
countries. It was estimated that by the end of 2010, about 80% of
HIV infected eligible patients were on ART [2,9].
In order to ensure a timely diagnosis of HIV for all, the Ministry
of Health (MOH) in Rwanda has planned the introduction of
provider initiated testing (PIT) in all its health facilities. Prior to
this, we studied linkage to care in four clinics in the capital Kigali,
and four in the northern district Musanze, to serve as baseline
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36792measurement prior to introduction of PIT. We examined the
proportion of HIV infected patients that enrolled at ART clinics,
the proportion of enrolled patients that were eligible for ART, and
the proportion of eligible patients that started ART, all within 90
days of diagnosis, and we examined clinic and patient factors
associated with enrolment, eligibility and start of ART.
Methods
Study setting
Data were obtained from facility-based registers in eight health
facilities in Rwanda: four facilities in Musanze district in the
North-West (Ruhengeri hospital, Muhoza health centre (HC),
Gasiza HC and Rwaza HC) and four facilities from Gasabo
district in the capital Kigali (Kibagabaga hospital, Kimironko HC,
Kinyinya HC and Kabuye HC). Data were studied from adults
and children aged 18 months or above registered at the out-patient
department (OPD), voluntary counselling and testing (VCT) clinic,
tuberculosis (TB) clinic and the antenatal care (ANC) clinic of the




Routine practice for HIV diagnosis and ART eligibility
In each of the eight health facilities HIV counselling and testing
was available. In most clinics the health worker referred the
patient to the laboratory, where a blood sample was taken and an
HIV test done, making use of an algorithm of three rapid tests
[10]. A patient who was diagnosed with HIV was referred to the
ART clinic within the same health facility, with the exception of
one clinic (Muhoza), from where patients were referred to the
neighbouring Ruhengeri hospital. After registration the patient
was examined by a physician who established in which WHO
stage the patient was [11]. A blood sample was taken to measure
the CD4 count. The patient was given an appointment to receive
the CD4 count result and advice regarding follow-up care and
treatment (Figure 1). At the time of the study, an HIV infected
patient (adult or child aged above 5 years) was eligible for ART
when the CD4 count was below 350 cells/mm
3 or was in WHO
clinical stage 4 [11]. The criteria for children below 5 years of age
were: CD4 count below 1500 cells/mm
3 (children below 11
months), CD4 count below 750 cells/mm
3 (children aged 12–35
months) and CD4 count below 350 cells/mm
3 (children aged 36–
59 months), and/or WHO clinical stage 3 or 4 [11]. Pulmonary
TB was regarded as a stage 3 disease. For TB patients newly
Figure 1. Routine flow of patients after HIV diagnosis, Rwanda, 2009.
doi:10.1371/journal.pone.0036792.g001
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after the start of TB treatment if the CD4 count was ,50 cells/
mm
3, between 15 days and 2 months after the start of TB
treatment if the CD4 count was between 50 and 200 cells/mm
3,
and 2 months after the start of TB treatment if the CD4 count
between 200 and 350 cells/mm
3 [12]. Before ART is started in
Rwanda social support must be ensured; this means that HIV
status should be disclosed to a family member or another close
person. Some patients diagnosed with HIV at TB departments
were being investigated for TB, but were not diagnosed with TB.
Data abstraction
For the purpose of the current study, registers from the above
mentioned departments, clinics and laboratories were abstracted
using structured forms. Link codes that appeared both in the
laboratory and the clinical registers were used to identify HIV
infected patients. ART clinics did not use the same link codes.
Registers from diagnosing departments were extracted for the
period 1
st March to 31
st May 2009, and a list of all patients
diagnosed with HIV during the study period (including, among
other demographic information, the name of the patient) was
generated to enable linkage between the testing clinic and the
ART clinic registers. The ART clinic registers were abstracted for
the period 1
st March to 31
st August 2009 using a standardised
form. After data abstraction, the names of study participants were
erased from the forms.
Data on the following variables were abstracted: study site
(health facility), department of HIV testing, age, sex, whether data
on the patient were found in the ART register (yes/no), date of
first visit at ART clinic, CD4 count, date of CD4 test, WHO stage,
date of WHO staging, date of start of ART (if applicable). Data
were entered by data entry clerks into EpiData 3.1 (EpiData
Association 2008, Odense, Denmark); subsequently the electronic
data were checked against the data collection forms by one of the
investigators. We used Stata version 9 (Stata Corporation, College
Station, TX, USA) for all data analyses.
Analysis
The proportion of patients enrolled into HIV care and
treatment was calculated as the number of HIV infected patients
registered in ART clinic registers within 90 days of their HIV
diagnosis divided by the total number of persons diagnosed in the
study period. The proportion of patients that was eligible for ART
was calculated as the number of patients who were eligible based
on WHO stage or CD4 count, divided by the total number of
patients of whom WHO stage and CD4 count were available.
Figure 2. Flow of HIV positive patients’ enrolment into HIV care and treatment, Rwanda, 2009.
doi:10.1371/journal.pone.0036792.g002
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of HIV diagnosis was determined by dividing the number of
eligible patients who started ART within 90 days by the number
eligible for ART.
Associations between age group, sex, department of HIV
diagnosis, study site and five outcomes (enrolled in care; CD4
count; WHO stage; eligible for ART; started ART) were assessed
using the chi-squared test, Fisher’s exact test or Kruskal-Wallis
test, as appropriate.
Multivariable logistic regression analyses were done to identify
factors associated with patient enrolment in care and treatment,
advanced clinical disease stage (WHO stage 3 or 4) and low CD4
count (,350 cells/mm
3). Because we assessed the effect of only
four independent variables, they were all included in the
multivariable model. P values of ,0.05 were considered statisti-
cally significant.
Ethics
Ethical approval was provided by the Rwandan National Ethics
Committee and the research ethics committee of the Academic
Medical Center, Amsterdam. All patients are aware that as part of
clinical care their demographic and clinical data are registered in
paper-based clinic registers. As only such routinely collected data
were abstracted from clinic registers, and no names were entered
into the electronic study database the ethics committees did not
require that written informed consent was sought from patients.
Results
Of the 525 patients diagnosed with HIV in the eight clinics
between 1
st March and 31
st May 2009, 43 were excluded from the
analysis due to non-matching link codes between the registers or
missing patient names, leaving 482 HIV patients for analysis
(Figure 2).
Enrolment in care and treatment
Table 1 shows the number of newly diagnosed HIV patients by
department, age group, sex, and study site. The majority (293;
61%) of HIV patients were diagnosed in VCT departments.
Seventy percent of the study patients (339) were female. The
median age of patients was 29 years (interquartile range [IQR]
24–37). Almost one third of all patients were diagnosed at Muhoza
clinic, a large urban clinic in north-west Rwanda.
Among the 482 patients, 201 (42%) enrolled in care and
treatment within 90 days of HIV diagnosis (see Table 2). For those
enrolled within 90 days of HIV testing, the median time (IQR)
between HIV testing and enrolment into care and treatment was 6
days (2–14). After seven days 115 patients (24%) had enrolled, by
30 days 180 (37%) and by 60 days 193 (40%) (see Figure 3.a).
Twenty-one patients (4%) enrolled after 30 days and only eight
(2%) after 60 days. There was a significant variation in the
proportion of patients enrolled in care and treatment between
study sites (p,0.001). Patients at all other sites other than Muhoza
(the largest clinic) were more likely to be enrolled within 90 days
(50% vs. 24%, p,0.001). Similar proportions of males and females
enrolled in HIV care and treatment (43% and 41% respectively;
p=0.6). Age was not significantly associated with enrolment
(p=0.25). Differences in enrolment between departments where
the HIV diagnosis was made were not statistically significant
(p=0.14).
When we defined enrolment not as being registered at the ARV
clinic but as a CD4 count having been done, the proportion
enrolled was 39% (188/482) and median time to enrolment
among those who enrolled was 6 days (2–13 days).
CD4 count and WHO stage
Of the 201 HIV patients that enrolled in care and treatment,
WHO staging and CD4 counts were done for 89% (179/201) and
94% (188/201) respectively; both WHO stage and CD4 count
Table 1. Number of newly diagnosed HIV infected patients, by department, sex, age and study site, Rwanda, March-May 2009.
Study sites Total (%)
Muhoza Ruhengeri Gasiza Kibagabaga Kinyinya Kimironko Rwaza Kabuye
Total 154 6 17 85 50 99 24 47 482 (100)
Department
VCT 117 NA 10 34 26 62 5 39 293 (60.8)
ANC 31 NA 2 11 17 30 0 8 99 (20.5)
TB NA 3 0 3 3 0 1 0 10 (2.1)
OPD 6 3 5 37 4 7 18 0 80 (16.6)
Age group
0–4 years 3 0 0 1 1 1 1 0 7 (1.5)
5–14 years 1 0 0 0 1 0 0 1 3 (0.6)
15–24 years 47 0 1 20 12 31 2 8 121 (25.6)
25–34 years 65 1 6 34 20 40 4 22 192 (40.6)
35–44 years 26 2 7 8 12 19 10 13 97 (20.5)
.45 years 12 3 3 13 4 8 7 3 53 (11.2)
Missing 0 0 0 9 0 0 0 0 9
Sex
Male 32 2 4 34 17 23 14 17 143 (29.7)
Female 122 4 13 51 33 76 10 30 339 (70.3)
NA=Not Applicable; TB Tuberculosis; ANC Antenatal care; HIV Human immunodefiency virus; OPD Outpatient department; VCT Voluntary counselling and testing.
doi:10.1371/journal.pone.0036792.t001
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were less than 15 years of age and were excluded from further
analysis. The medium time between HIV diagnosis and CD4
count was 6 days (IQR 2–13).
The median CD4 count among 185 adult patients was 387
cells/mm
3 (IQR: 242 to 533 cells/mm
3). Forty-three percent has a
CD4 count below 350 cells/mm
3; 40 patients (22%) had a CD4
count below 200 cells/mm
3. The median CD4 count of males was
lower than that of females (330 vs. 412 cells/mm
3; p=0.01; see
Table 2). Patients diagnosed at OPDs and TB units had lower
median CD4 counts (respectively 287 and 188 cells/mm
3) than
those enrolled at VCT or ANC (p=0.0002).
In univariable analysis, low CD4 count (defined by a CD4 count
,350 cells/mm
3) was significantly associated with department,
age, and sex (p=0.006, p=0.008, and p=0.03 respectively), but
not with study site (see Table 3). Multivariable logistic regression
analysis revealed only age as an independent factor: older age was
associated with lower CD4 counts (p=0.02).
Among the 198 enrolled adult patients, 107 were in WHO stage
1, 41 in stage 2, 28 in stage 3 and none were in stage 4 (for 22
patients no WHO stage was recorded). WHO stage 3 or 4 was
associated with study site, department and age (all p,0.005), but
not with sex (p=0.17). In multivariable logistic regression analysis
department of HIV diagnosis was significantly associated with an
advanced WHO stage (those diagnosed at ANC being less likely
and those diagnosed at the TB department being more likely to
have WHO stage 3/4); older age was associated with advanced
WHO stage. As there were no patients in WHO stage 4, the
analysis of determinants for ART eligibility was basically identical
to the one analysing determinants of low CD4 counts (see above).
Start of ART
Of the 81 eligible patients 45 (56%) started ART within 90 days
of HIV diagnosis. For those who started ART within 90 days, the
median time (IQR) between date of HIV diagnosis and start of
ART was 30 days (18–43). After seven days none of the patients
had started ART, by 30 days 24 (30%) and by 60 days 41 (51%)
(see Figure 3.b). Twenty-one of eligible patients (25%) started
ART more than 30 days after HIV diagnosis, but only 4 (5%)
started ART after 60 days For those who started ART within 90
days, the median time between date of CD4 count and start of
ART was 22 days (IQR 13–37). A statistically significant
association was observed between the study site and the start of
ART (p,0.001; see Table 2). At three of the eight study sites all
ART eligible patients started treatment within 90 days of HIV
diagnosis; at one site less than 20%. A higher proportion of eligible
females than males started ART (63% vs. 46%), but this was not
significant (p=0.13). Neither department nor age were associated
with start of ART (p=0.64 and p=0.52 respectively). Numbers
were too small to perform multivariable analysis.
Children
There were 10 children among the 482 patients: four boys and
six girls. Their median age was 3 years (range 1–9 years old). The
children were identified in six sites; two of them were tested in
OPD and eight at the VCT department. Only three of the ten
children enrolled at care at ARV clinics, were staged and had CD4
counts measured. One of them had a low CD4 count and was in
stage 2; the other two had normal CD4 counts and were in stage 1.




Following HIV diagnosis, registration at ART clinics is crucial
for assessment of treatment eligibility, counselling, and start of
ART. This study shows that a low proportion of HIV patients
Figure 3. a. Time to enrolment among 482 HIV patients. b. Time to
start of ART among 81 eligible HIV patients, from date of HIV diagnosis.
c. Time to start of ART among 81 eligible HIV patients, from date of CD4
test.
doi:10.1371/journal.pone.0036792.g003
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start of care and treatment within 90 days of HIV diagnosis. About
half of enrolled patients were eligible for ART, and just over half
those actually started ART within 90 days of diagnosis.
Enrolment
Other studies from sub-Saharan Africa (SSA) among people
diagnosed with HIV at VCT centres or out-patient departments
[4,8,13–15] reported higher enrolment proportions, varying from
55% in Durban (South Africa) [4] to 68% in South West Uganda
[8]. One study from South Africa reported a much higher
proportion, 85%, but in that setting CD4 counting was done at the
same visit as the HIV test [16]. A study from Lusaka, Zambia,
reported a much lower proportion, 38% [6].
Studies have used different cut-offs to calculate enrolment
(varying between 8 weeks and 6 months), but these differences do
not explain the variations in enrolment, as the median time to
enrolment tends to be counted in days rather than weeks, and few
are enrolled more than 4 weeks after the HIV diagnosis [6,7,13]
We defined enrolment into care and treatment as a first visit and
registration at the ART clinic. If we had used the definition of a
recent meta-analysis (date of CD4 count) [15] the enrolment
would have been 39% rather than 42%; this compares to the
median of 59% found in the systematic meta-analysis by Rosen &
Fox [15].
Table 2. Enrolment into HIV care & treatment, WHO stage, median CD4 count, ART-eligibility and start of ART by study site,
department, age and sex, Rwanda, 2009.
Total
Number (%) with 1
st
visit to ART clinic
Number (%) with















Total 482 201/482 (41.7) 28/176 (15.9) 387 (242–533) 81/170 (47.7) 45/81 (55.6)
Study site
Muhoza 154 37/154 (24.0) 6/37 (16.2) 366 (247–498) 20/37 (54.1) 13/20 (65.0)
Ruhengeri 6 6/6 (100.0) 4/6 (66.7) 264 (97–440) 5/6 (83.3) 1/5 (20.0)
Gasiza 17 6/17 (35.3) 3/6 (50.0) 299 (112–417) 4/6 (66.7) 4/4 (100.0)
Kibagabaga 85 38/85 (44.7) 1/28 (3.6) 431 (258–551) 9/28 (32.1) 9/9 (100.0)
Kinyinya 50 21/50 (42.0) 2/18 (11.1) 381 (96–492) 6/14 (42.9) 4/6 (66.7)
Kimironko 99 62/99 (62.6) 8/56 (14.3) 392 (273–536) 26/54 (48.2) 5/26 (19.2)
Rwaza 24 12/24 (50.0) 3/11 (27.3) 369 (160–388) 6/11 (54.6) 4/6 (66.7)
Kabuye 47 19/47 (40.4) 1/14 (7.1) 588 (288–824) 5/14 (35.7) 5/5 (100.0)
p-value
f ,0.001 0.005 0.179 0.314 ,0.001
Department
VCT 293 113/293 (38.6) 15/101 (14.9) 405 (279–564) 43/99 (44.3) 23/43 (53.5)
ANC 99 46/99 (46.5) 1/38 (2.6) 469 (269–565) 11/37 (29.7) 7/11 (63.6)
TB 10 7/10 (70.0) 4/7 (57.1) 188 (22–340) 6/7 (85.7) 2/6 (33.0)
OPD 80 35/80 (43.8) 8/30 (26.7) 287 (112–387) 21/29 (72.4) 13/21 (61.9)
p-value
f 0.139 0.001 0.0002 ,0.001 0.644
Age
0–4 7 1/7 (14.3) N.A. N.A. N.A. N.A.
5–14 3 2/3 (66.7) N.A. N.A. N.A. N.A.
15–24 121 51/121 (42.2) 4/44 (9.1) 476 (349–623) 11/42 (26.2) 5/11 (45.5)
25–34 192 79/192 (41.2) 8/69 (11.6) 422 (266–583) 31/68 (45.6) 15/31 (48.4)
35–44 97 39/97 (40.2) 4/35 (11.4) 344 (146–441) 18/33 (54.6) 12/18 (66.7)
.45 53 29/53 (54.7) 12/28 (42.9) 325 (192–378) 21/27 (77.8) 13/21 (61.9)
p-value
f 0.253 0.002 0.0010 ,0.001 0.518
Sex
Female 339 139/339 (41.0) 16/120 (13.3) 412 (259–558) 48/116 (41.4) 30/48 (62.5)
Male 143 62/143 (43.4) 12/56 (21.4) 330 (209–479) 33/54 (61.1) 15/33 (45.5)
p-value
f 0.632 0.171 0.0126 0.016 0.129
N.A. Not Applicable; TB Tuberculosis; ANC Antenatal care; HIV Human immunodefiency virus; OPD Outpatient department; VCT Voluntary counselling and testing; ART
antiretroviral treatment; IQR interquartile range; WHO World Health Organization.
aWHO stage was available for 179. Data provided are for the 176 patients aged 15 years or above.
bPatients with pulmonary TB and HIV infection are by definition in WHO stage 3; however not all patients diagnosed at TB clinics were confirmed TB cases.
cCD4 count results were available for 188/201. Data provided are on the 185 patients aged 15 years or above.
dART eligibility was based on CD4 count (CD4,350 cells/mm
3) and WHO stage (stage 4). Data provided are on the 170 patients aged 15 years or above.
eAmong those who were eligible for ART. Data provided are on the 81 patients aged 15 years or above.
fThe p-values are based on chi-squared test, Fisher’s exact test or Kruskal-Wallis test, as appropriate.
doi:10.1371/journal.pone.0036792.t002
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programs. The low overall enrollment in our study was strongly
influenced by one large clinic with only 24% enrolment. The
enrolment in all other clinic combined was 50%. The clinic with
the low enrolment rate was the only site that had to refer patients
off-site to an ARV clinic. Neither age nor sex of patients was
associated with enrolment, but health facility was. This suggests
that health services should be improved to enable a more
successful transfer of patients from diagnosing clinic to ART
clinic. It also suggests that presence of an ARV clinic at the HIV
testing site may be conducive for high enrolment. This appears a
relatively straightforward and achievable approach to increase
enrolment and uptake of ART.
Eligibility
The median CD4 count of the HIV patients who enrolled into
care was quite high (387 cells/mm
3) compared to the average CD4
count in many other HIV programs in sub-Saharan Africa [17]
and elsewhere. At the time of this study (2009) Rwanda already
used the 350 cells/mm
3 cut-off for treatment eligibility. Thus, in
spite of the generally high CD4 count in the study population, less
than half of the enrolled patients in our study were eligible for
immediate ART. Few patients were in very advanced stage of
infection (none in WHO stage 4 and only 9% with CD4 count
below 100 cells/mm
3). Provider-initiated testing could potentially
lead to early HIV diagnosis and a timely start of ART for even
more people.
Start of antiretroviral treatment
Fifty-six percent of eligible patients had started ART within 90
days of HIV diagnosis. This proportion is too low and indicates
delays. Other studies from SSA [5,13,14,18] reported that
between 67% [14] and 86% [18] of eligible patients started
ART within 3 to 6 months. If we restrict our analysis to those who
are eligible based on the criterion used in most other studies (,200
cells/mm
3), [5,13,19] only 22% of patients would have been
eligible; 68% of these started ART ,90 days after diagnosis,
which is more in line with other studies done in sub-Saharan
Africa.
Table 3. Factors associated with non-enrolment, high WHO stage and CD4 count ,350 cells/mm
3 among adult HIV patients
diagnosed in eight Rwanda health facilities, 2009: logistic regression.
Non enrolment WHO stage 3 or 4 CD4 count ,350 cells/mm
3
n/N OR (95%CI) n/N OR (95%CI) n/N OR (95%CI)
274/472 28/176 79/185
Study sites
Muhoza 113/150 1 6/37 1 17/37 1
Ruhengeri 0/6 N.A. 4/6 10.3 (1.5–69.7) 4/6 2.4 (0.4–14.5)
Gasiza 11/17 0.6 (0.2–1.7) 3/6 5.2 (0.8–32.0) 4/6 2.4 (0.4–14.5)
Kibagabaga 46/84 0.4 (0.2–0.7) 1/28 0.2 (0.02–1.7) 13/34 0.7 (0.3–1.9)
Kinyinya 28/48 0.5 (0.2–0.9) 2/18 0.6 (0.1–3.6) 6/14 0.9 (0.3–3.1)
Kimironko 36/98 0.2 (0.1–0.3) 8/56 0.9 (0.3–.2.7) 25/60 0.8 (0.4–1.9)
Rwaza 12/23 0.4 (0.1–0.9) 3/11 1.9 (0.4–9.5) 5/11 1.0 (0.3–3.8)
Kabuye 28/46 0.5 (0.3–1.0) 1/14 0.4 (0.04–3.6) 5/17 0.5 (0.1–1.7)
p-value ,0.0001 0.011 0.712
Departments
VCT 174/285 1 15/101 1 40/104 1
ANC 53/99 0.7 (0.5–1.2) 1/38 0.15 (0.02–1.2) 14/43 0.8 (0.4–1.6)
TB 3/10 0.3 (0.1–1.1) 4/7 7.6 (1.6–37.6) 6/7 9.6 (1.1–82.7)
OPD 44/78 0.8 (0.5–1.4) 8/30 2.1 (0.8–5.5) 19/31 2.5 (1.1–5.8)
p-value 0.159 0.0013 0.0058
Age
15–24 years 70/121 1.7 (0.9–3.2) 4/44 0.1 (0.04–0.5) 12/46 0.2 (0.07–0.5)
25–34 years 113/192 1.7 (0.9–3.2) 8/69 0.2 (0.1–0.5) 31/76 0.4 (0.2–0.9)
35–44 years 58/97 1.8 (0.9–3.5) 4/35 0.2 (0.05–0.6) 18/35 0.6 (0.2–1.6)
.45 years 24/53 1 12/28 1 18/28 1
p-value 0.316 0.002 0.0076
Sex
Female 195/333 1 16/120 1 48/128 1
Male 79/139 0.9 (0.6–1.4) 12/56 1.8 (0.8–4.1) 31/57 2.0 (1.1–3.7)
p-value 0.730 0.180 0.0335
Those aged ,15 years were excluded from these analyses. NA=Not Applicable; TB Tuberculosis; ANC Antenatal care; HIV Human immunodefiency virus; OPD
Outpatient department; VCT Voluntary counselling and testing; WHO World Health Organization.
doi:10.1371/journal.pone.0036792.t003
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higher proportion of men than women (61% vs. 41%; p=0.016)
was eligible for immediate start of ART. This indicates that men
are diagnosed later in their HIV disease course than women. This
may be a reason for the higher mortality among HIV infected men
on ART, observed in other studies [23–26]. Older patients were at
a more advanced disease stage than young people at the time of
diagnosis, both in terms of clinical condition (WHO stage) and in
terms of CD4 count. This finding was independent of sex, so is not
just caused by the large number of, predominantly younger,
pregnant and delivering women. More testing of older adults (aged
above 35 years) should be encouraged and PIT has the potential to
address this issue.
Universal access and linkage to care and treatment in
Rwanda
A recent report of WHO/UNAIDS indicated that worldwide
only three countries with a generalized HIV epidemic have
achieved universal access of ART (defined as providing antiret-
roviral therapy to at least 80% of the people eligible for treatment),
Rwanda being one of those three countries [2]. Our finding of low
linkage to care and treatment after HIV diagnosis may appear
paradoxical in view of this remarkably high ART coverage. There
may be several explanations for this. In Rwanda HIV testing rates
among the population are high and it is thought that the majority
of HIV infected people know their status. This is the case for those
eligible for treatment as well as those not yet eligible. Nevertheless,
a significant proportion of people have never been tested. If the
people diagnosed with HIV infection in our study were not
previously aware of their status, it is to be expected that a fair
proportion of them will be eligible for immediate ART.
Qualitative research by our group (unpublished; work in progress)
found that several patients being tested for HIV at health facilities
had already had a positive HIV test before. Some sought another
HIV test because they did not believe the initial positive result;
others hoped they would have cleared the infection spontaneously;
and some had initially been tested at another clinic than their own
neighbourhood clinic. Due to this ‘‘repeat positive testing’’, the
observed enrolment may be an underestimate. Our results suggest
that even in a program with very high coverage of ART,
improvements can still be made.
Limitations
Our study was subject to certain limitations. Some errors in
patient identifiers (names, age, sex, department of initial consul-
tation) between registers posed a problem of identification of some
study patients. This resulted in the exclusion of 8% of patients.
Field staff may have overlooked names in the ART registers of
people that were actually on their list of HIV infected patients, due
to unclear writing, variations in spelling of names, or usage of
different names. In some cases patients did start ART but dates of
start were missing; this contributed to a lower estimated
proportion of patients that started ART. The selection of health
facilities was not random, so the findings may not be generalizable
to Rwanda as a whole. It is unlikely that patients attended other
ART clinics than the ones they were referred to, as no functional
referral system between clinics was in place at the time of the
study; patients presenting at another clinic than the one they were
originally tested at, would normally be tested again for HIV at that
clinic before they would be registered, assessed for eligibility or
started on ART. Possibly the requirement of disclosure of HIV
status to family members prior to HAART initiation may have
played a role in the low enrolment rate, but as this analysis used
routine clinic data we were unable to assess this.
The main strength of our study is that we used routine data
from primary care clinics and hospitals, reflecting routine health
care practice, rather than using data from research clinics where
quality of referral and assessment may be better.
Conclusion
Less than 50% of people were enrolled at an HIV care clinic
within 90 days of their HIV diagnosis. We found no association
between age or sex of the patient and enrolment, but enrolment
varied substantially between health facilities. Thus, improving
linkage between clinics of testing and ART clinics could increase
ART coverage. Just over half of eligible patients started ART
within 90 days of diagnosis. Targeted efforts to improve pre-ART
patient retention are needed.
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